Publications by authors named "F Fimognari"
Background: High-income countries are currently decreasing length of hospital stay (LOS), with the aim of improving resource utilization. Little is known about the contribution of LOS to short-term post-discharge mortality in older patients with pneumonia.
Aim: to identify factors independently associated with LOS and to determine whether LOS predicts 3-month post-discharge death in older patients hospitalized for pneumonia.
Background: Prevalence, correlates and outcomes of respiratory failure (RF) were never studied in large populations of older patients hospitalized in acute care medical settings. Little is known about the possible association between RF and delirium, and whether these two syndromes, alone or in combination, may affect short-term mortality.
Objectives: To investigate prevalence and features of RF, the association between delirium and RF, and their effect on short-term mortality.
Article Synopsis
- * Non-invasive ventilation (NIV) and high-flow nasal cannula oxygen therapy (HFNC) provide necessary respiratory support during these procedures.
- * A successful case study involving a 78-year-old patient with ARF showed that combining HFNC with multiple FBOs improved his condition and allowed similar treatments for other ARF patients, suggesting this combination could be a safe alternative to intubation in elderly patients facing severe airway obstruction.
Respiratory failure (RF) is frequent in hospitalized older patients, but was never systematically investigated in large populations of older hospitalized patients. We conducted a retrospective administrative study based on hospitalizations of a Geriatrics Unit regarding 2014, 2015, and 2016. Patients underwent daily screening for hypoxia.
View Article and Find Full Text PDFGlasdegib for the treatment of acute myeloid leukemia.
Expert Opin Pharmacother
November 2023
Introduction: Over the last few years, substantial progress has been made in the management of acute myeloid leukemia (AML). The first changes in the management of AML date back to last 2000s with the advent of hypometilant agents, later with Bcl2 inhibitor venetoclax, and Fms-like tyrosine kinase 3 (FLT3) inhibitors (midostaurin and gilteritinib), and more recently with IDH1/2 inhibitors (ivosidenib and enasidenib) and the hedgehog (HH) pathway inhibitor glasdegib.
Areas Covered: Glasdegid, formerly PF-04449913 or PF-913, acts as a smoothened (SMO) inhibitor and has been recently approved in combination with low-dose cytarabine (LDAC) by FDA and EMA for the treatment of naïve AML patients unfit for intensive chemotherapy.